Skip to main content

Leuphasyl vs MOTS-c

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Leuphasyl

Leuphasyl (Pentapeptide-18) is a cosmetic peptide that reduces muscle tension through a mechanism similar to enkephalins. Often combined with Syn-Ake for enhanced anti-wrinkle effects.

Full details →

MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.

Full details →

Side-by-Side Comparison

AspectLeuphasylMOTS-c
MechanismMimics enkephalin and binds to enkephalin receptors on muscle cells, reducing acetylcholine release and thereby decreasing muscle contraction intensity.Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis.
Typical DosageTopical: 3-8% concentration in serums. Often used in combination products with other muscle-relaxing peptides.Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established.
AdministrationTopical application to expression lines. Best results with consistent twice-daily use over 8+ weeks.Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation.
Side EffectsVery well-tolerated topically. No significant adverse effects reported at cosmetic concentrations.Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance.
Best For

Key Differences

Detailed Analysis

Commonalities

Leuphasyl and MOTS-c are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Leuphasyl for Skin Health & Aesthetics. Choose MOTS-c for Muscle Growth, Fat Loss, Anti-Aging & Longevity.

Ready to Learn More?